Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Quality Risk Management: Risk Control and Risk-Based Decision-Making - July

Jul 10 - Jul 11, 2018 |
Jul 11, 2018 |
PDA Training and Research Institute | Bethesda, MD
  • Education
Add event to: ICal Outlook Google Calendar
Duration:  2 days
Time: 8:30 a.m. - 4:00 p.m.

To control risk, decisions must be made as part of the quality risk management (QRM) process. Risk-based decision-making tends to be more dynamic and less structured than the other steps of the QRM process. A decision-maker’s role in the QRM process is critical for timely, effective and ongoing management of risks. The course will provide participants with the ability to interpret the appropriateness and adequacy of risk control mechanisms. Attendees will also explore the overall concepts of risk-based decision-making including risk tolerance, its impact on the success of risk management, and how to manage diversity in risk tolerance across your organization. The course will strengthen learners’ competencies to identify and assess the results of a QRM exercise in order to enable robust risk-based decisions and enable success of QRM activities.


IMPORTANT NOTE: Participants enrolling in this course must have completed one of the following PDA courses:

  • Foundations of Quality Risk Management scheduled on December 11, 2017 or July 9, 2018 at the PDA Training and Research Institute in Bethesda, Maryland.
  • Any offerings of the prior PDA course, Implementing Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Additionally, participants should have read PDA Technical Report 54 (TR 54), Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations.

Who Should Attend

The QRM Decision Maker track includes two courses: “Foundations of Quality Risk Management” and “Quality Risk Management: Risk Control and Risk-Based Decision-Making.” This training module is applicable to supervisors, managers and directors from disciplines such as quality assurance, quality control, engineering, validation, production and technical services, who often make decisions based on the outcomes of risk assessments for their areas of responsibility.

Upon completion of this course, you will be able to:

  • Explain the roles and responsibilities of decision makers in the QRM process
  • Assess the elements of risk-based decision making
  • Apply risk-based decision principles as part of QRM activities
  • Use risk assessment outcomes and risk register to define the most appropriate risk mitigation strategy
  • Differentiate between the types of risk control mechanisms and how to apply them
  • Examine how level of risk tolerance in an organization can impact risk control priorities and ultimately the effectiveness of QRM



On or before May 25, 2018

After May 25, 2018


On or before May 25, 2018

After May 25, 2018

Government/Health Authority/Academic



All rates in US Dollars. REFUND FOR COURSES: If your written request is received by June 11, 2018, you will receive a full refund less a $200 processing fee. After that time, no refunds will be approved. COURSE CANCELLATION: PDA reserves the right to modify the material or instructors without notice, or to cancel an event. If an event must be cancelled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancellation. For more details, contact PDA at or +1 (301) 656-5900.

General Course Information

Please arrive at the course location approximately thirty minutes before the start of the course to sign in. Please be sure to bring your confirmation letter as proof of registration. PDA will not allow persons to attend a course without payment, or guarantee of payment.

Breakfast will be served thirty minutes before the class begins. Lunch will be provided between 12:00 - 1:00 p.m.


The course will be held at:

PDA Training and Research Institute
Bethesda Towers
4350 East West Highway, Suite 110
Bethesda, MD 20814 USA

Recommended Hotel

Hilton Garden Inn Bethesda
7301 Waverly Street | Bethesda, MD 20814 | 0.3 miles from PDA
(301) 654-8111


For more information, please contact:

Stephanie Ko
Senior Manager, Lecture Education
Tel: +1 (301) 656-5900 x151

Amanda B. McFarland, Senior Consultant, Valsource, LLC

Amanda Bishop McFarland, M.S. is a Quality Risk Management and Microbiology Consultant with Valsource, LLC with over 15 years industry experience. She specializes in the creation and implementation of Risk Management programs and in developing risk-based strategies for use in Microbiology. She has a Bachelors of Science (Entomology) and a Masters of Science in Mycology both from the University of Florida. Amanda is an active member of the Parenteral Drug Association (PDA); a faculty member of the PDA’s Quality Risk Management training series and the Quality Risk Management Interest Group co-lead.

Emma Ramnarine, Senior Director, Head, Global Analytical Science & Technology, Genentech/Roche

Emma Ramnarine is accountable for the strategic direction and leadership for analytical methods, technologies, and control systems for Roche’s commercial Biologics and Small Molecule products — includes establishing and maintaining up-to-date, compliant and harmonized analytical control systems, proactive lifecycle management, technology innovation, method transfers, stability program, raw materials and reference standards management.

Emma has over 17 years of experience in the pharmaceutical, biotechnology and medical device industry in Quality System Management including developing and leading Quality Risk Management (QRM) programs. She is a worldwide-recognized expert on QRM, providing QRM leadership, governance, guidance, and training to regulatory authorities and at industry forums. She led the Task Forces for PCMOSM Technical Report Series No. 54 on “Implementation of Quality Risk Management”. She also led PDA’s Task Force for Technical Report No. 68 on “Risk Based Approach for Prevention and Management of Drug Shortages”, and is a representative for PDA on the inter-association European Drug Shortages Team that was formed under EMA’s direction.

Emma currently co-leads PDA’s Post Approval Change Task Force; she is on the PDA Board of Directors, PDA’s Regulatory Affairs and Quality Advisory Board (RAQAB), leads PDA’s QRM Interest Group, and has led the development of several PDA Technical Reports.

H. Gregg Claycamp, PhD, Senior Biomedical Research Scientist, Risk Analysis and Decision Analysis, U.S. FDA

Dr. Claycamp is a Senior Biomedical Research Service (SBRS) appointee whose duties include Risk Analysis and Decision Analysis in the Office of New Animal Drugs (CVM). He joined the FDA in 2001 to work on human health risk assessment from drugs approved for use in food animals in addition to a variety of risk analysis and decision analysis for regulatory scientific review and compliance problems. Since 2001 he also served as Director of the Div. of Compliance Risk Management and Surveillance in the Center for Drug Evaluation and Research (CDER) Office of Compliance. Dr. Claycamp continues to work on a portfolio of risk problems, risk management systems, and decision analysis tools for various levels of drug review and post-marketing risk management. He frequently speaks at industry and scientific conferences and publishes on these topics; reviews for a variety of risk and regulatory science journals; and teaches FDA courses in Risk Analysis and Risk-Informed Decision Making. Dr. Claycamp also serves on international working groups who developed “quality risk management” as a systems-based approach integrating quality systems and risk management for drug manufacturing. He was the regulatory lead for the final, internationally-harmonized guideline, "ICH Q9: Quality Risk Management” ( Presently, he is part of the design and delivery of risk management training for the PIC/S organization, which now include ~50 regulatory agencies worldwide. Dr. Claycamp’s AB is in Human Biology from Stanford University; MS and PhD degrees are in Radiological Health Engineering from Northwestern University. Prior to joining FDA, Dr. Claycamp was a Professor at the University of Pittsburgh where he directed graduate training programs in Risk Assessment and Radiation Health while maintaining an active research career including 70+ publications. He previously served on faculties of Radiation Biophysics at the Univ. of Kansas and the Dept. of Radiology at the Univ. of Iowa.

Continuing Education for Pharmacists

ACPE PDA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants may sign up to receive Continuing Pharmacy Education (CPE) credits. To do so, participants must sign in at the beginning of the program, submit the provided evaluation forms and mail the CPE credit request to the address stated on the form. Attendees must be present at the full event to receive Continuing Pharmacy Education credit, which will be awarded as follows:

PDA #530 | ACPE #0116-0000-17-015-L04-P | 1.2 CEUs
Type of Activity: Application

Continuing Education for Professional Engineers

New Jersey

PDA is an approved provider by the New Jersey State Board of Professional Engineers and Land Surveyors to offer courses to New Jersey Professional Engineers for Continuing Professional Competency (CPC) credit. Following the full participation in this course, participants will receive a Certificate of Accomplishment specifying the number of CPC credits that may be awarded. This certificate can be submitted as verification of completion to the Board for license renewal.

The credit value of this course is 12 CPC credits.

North Carolina

PDA is recognized by the North Carolina Board of Examiners for Engineers and Surveyors as an Approved Sponsor of Continuing Professional Competency (CPC) activities for Professional Engineers licensed by North Carolina. To receive a Certificate of Accomplishment specifying the number of Professional Development Hours (PDHs) that may be awarded, course participants must request the North Carolina Board of Examiners evaluation form from PDA staff. This form must be completed onsite at the conclusion of the course and returned to PDA staff.

The credit value of this course is 12 PDHs.